Maintenance Therapy in Multiple Myeloma Patients
Author Information
Author(s): A. Belch, W. Shelley, D. Bergsagel, K. Wilson, P. Klimo, D. White, A. Willan
Primary Institution: University of Alberta
Hypothesis
Does maintenance therapy with melphalan and prednisone improve outcomes in multiple myeloma patients who have responded to initial treatment?
Conclusion
Maintenance therapy does not significantly improve survival in multiple myeloma patients who have stabilized after initial treatment.
Supporting Evidence
- 57% of patients in the no maintenance group had a second response when treatment was restarted.
- The median time to first relapse was shorter in the no maintenance group.
- The average total dose of melphalan was significantly lower in the no maintenance group.
Takeaway
This study looked at whether continuing treatment helps patients with multiple myeloma after they start feeling better. It found that stopping treatment doesn't hurt their chances of living longer.
Methodology
Patients who responded to initial treatment were randomized to either continue or stop treatment until relapse, and their outcomes were compared.
Limitations
The study may not have identified all subgroups that could benefit from maintenance therapy, and the follow-up duration may not be sufficient to assess long-term effects.
Participant Demographics
{"median_age":62,"gender_distribution":{"male_percentage":52,"female_percentage":48}}
Statistical Information
P-Value
0.0011
Statistical Significance
p=0.0011
Want to read the original?
Access the complete publication on the publisher's website